The unfolded protein response mediates reversible tau phosphorylation induced by metabolic stress
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The unfolded protein response (UPR) is activated in neurodegenerative tauopathies such as Alzheimer's disease (AD) in close connection with early stages of tau pathology. Metabolic disturbances are strongly associated with increased risk for AD and are a potent inducer of the UPR. Here, we demonstrate that metabolic stress induces the phosphorylation of endogenous tau via activation of the UPR. Strikingly, upon restoration of the metabolic homeostasis, not only the levels of the UPR markers pPERK, pIRE1α and BiP, but also tau phosphorylation are reversed both in cell models as well as in torpor, a physiological hypometabolic model in vivo. Intervention in the UPR using the global UPR inhibitor TUDCA or a specific small-molecule inhibitor of the PERK signaling pathway, inhibits the metabolic stress-induced phosphorylation of tau. These data support a role for UPR-mediated tau phosphorylation as part of an adaptive response to metabolic stress. Failure to restore the metabolic homeostasis will lead to prolonged UPR activation and tau phosphorylation, and may thus contribute to AD pathogenesis. We demonstrate that the UPR is functionally involved in the early stages of tau pathology. Our data indicate that targeting of the UPR may be employed for early intervention in tau-related neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 1×
“Several neurodegenerative disorders are characterized by abnormal phosphorylation and aggregation of the neuronspecific microtubule-binding protein tau.(1) These so-called tauopathies include highly prevalent neurodegenerative disorders as Alzheimer’s disease (AD) and tau-related”
BackgroundTalbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Differential Regulation of Dynein and Kinesin Motor Proteins by Tau
Dixit, R., Ross, J. L., Goldman, Y. E., & Holzbaur, E. L. F. (2008) · Science · doi:10.1126/science.1152993 · Cited by 1,012 · cited 1×
“Phosphorylation of tau reduces the binding of tau to microtubules and regulates the function of tau in axonal transport.(2)”
BackgroundIncreased Risk of Type 2 Diabetes in Alzheimer Disease
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.474 · Cited by 950 · cited 1×
“The majority of AD patients display abnormal glucose metabolism, ranging from glucose intolerance to insulin resistance and type 2 diabetes mellitus.(28) A reduced glucose metabolic rate is already observed in patients that are genetically predisposed to develop AD before any pathological signs of the diseasemanifest.”
BackgroundCerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090106797 · Cited by 790 · cited 1×
“A reduced glucose metabolic rate is already observed in patients that are genetically predisposed to develop AD before any pathological signs of the diseasemanifest.(29,30) Moreover, glucose metabolism is also decreased in brains of patients with mild cognitive impairment, which is a prodromal stage of AD.”
BackgroundThe Unfolded Protein Response Is Activated in Pretangle Neurons in Alzheimer's Disease Hippocampus
Hoozemans, J. J. M., van Haastert, E. S., Nijholt, D. A. T., Rozemuller, A. J. M., Eikelenboom, P., & Scheper, W. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080814 · Cited by 600
Self-citationMoreno, J. A., Halliday, M., Molloy, C., Radford, H., Verity, N., Axten, J. M., Ortori, C. A., Willis, A. E., Fischer, P. M., Barrett, D. A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006767 · Cited by 589
Endoplasmic reticulum dysfunction in neurological disease
Roussel, B. D., Kruppa, A. J., Miranda, E., Crowther, D. C., Lomas, D. A., & Marciniak, S. J. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70238-7 · Cited by 441 · cited 1×
“the frame as an early therapeutic target for neurodegenerative diseases.(40,41) In fact, interference in the UPR by deletion of the gene encoding PERK, EIF2AK3, or by administration of a”
BackgroundGWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease
Cruchaga, C., Kauwe, J. S. K., Harari, O., Jin, S. C., Cai, Y., Karch, C. M., Benitez, B. A., Jeng, A. T., Skorupa, T., Carrell, D., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.026 · Cited by 383 · cited 1×
“major factor in glucose metabolism, was associated with increased tau levels in the cerebrospinal fluid, an early biomarker for AD-related changes in the brain.(36) Figure 5 Activation of the UPR during euthermia is consolidated during hypothermia.”
Background
Cited by
Roles of tau protein in health and disease
Guo, T., Noble, W., & Hanger, D. P. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1707-9 · Cited by 1,003
Halliday, M., Radford, H., Sekine, Y., Moreno, J., Verity, N., le Quesne, J., Ortori, C. A., Barrett, D. A., Fromont, C., Fischer, P. M., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.49 · Cited by 380
The unfolded protein response in neurodegenerative diseases: a neuropathological perspective
Scheper, W., & Hoozemans, J. J. M. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1462-8 · Cited by 367
Self-citationHalliday, M., Radford, H., Zents, K. A. M., Molloy, C., Moreno, J. A., Verity, N. C., Smith, E., Ortori, C. A., Barrett, D. A., Bushell, M., et al. (2017) · Brain · doi:10.1093/brain/awx074 · Cited by 293
PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia
Radford, H., Moreno, J. A., Verity, N., Halliday, M., & Mallucci, G. R. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1487-z · Cited by 293
Metadata
- Authors
- van der Harg, J. M., Nölle, A., Zwart, R., Boerema, A. S., van Haastert, E. S., Strijkstra, A. M., Hoozemans, J. J., & Scheper, W.
- Venue
- Cell Death & Disease
- Published
- 2014-08-28
- Volume
- 5
- Issue
- 8
- Pages
- e1393-e1393
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2026796723
- Cited by
- 88
- References
- 11
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The unfolded protein response mediates reversible tau phosphorylation induced by metabolic stress. https://app.cochat.ai/papers/10.1038/cddis.2014.354
- The paper
- van der Harg, J. M., Nölle, A., Zwart, R., Boerema, A. S., van Haastert, E. S., Strijkstra, A. M., Hoozemans, J. J., & Scheper, W. (2014). The unfolded protein response mediates reversible tau phosphorylation induced by metabolic stress. Cell Death & Disease. https://doi.org/10.1038/cddis.2014.354
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.